Physician profile
Dione Chua
NPI 1457668832
$1,110.89
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $17.87 · 2021: $35.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $204.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $203.21 | 2019 | |
| Lilly USA, LLC | $101.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.10 | 2019 | |
| Pfizer INC. | $75.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.62 | 2019-2020 | |
| Astellas Pharma US INC | $60.27 | 2019 | |
| Allergan, INC. | $49.79 | 2019 | |
| Amarin Pharma, INC. | $39.34 | 2019 | |
| Abbvie INC. | $35.98 | 2021 | |
| Amgen INC. | $34.56 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.61 | 2019 | |
| Glaxosmithkline, LLC. | $28.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.35 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $22.43 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18.10 | 2019 | |
| Mannkind Corporation | $17.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dione Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.